CEO Ray Gilmartin Merck’s CEO Ray Gilmartin is a significant stakeholder in the company. Since a lot of Mercks’ products patents will be expiring in the next few years Gilmartin put a big emphasis on investing into the companies research and development of new products. Gilmartin wanted this company to really focus on coming out with new products because their bottom line was going to take a hit in the next few years once the patent on their big money products runs out. Gilmartin found it an
Premium Pharmacology Finance Management occupations
Merck‚ the FDA‚ and the VIOXX Recall MBA 520-D4C2 Ethics & Leadership in a Global Environment April 22‚ 2012 Merck and Vioxx Recall Did Merck act in social and ethical manner? In 2005‚ Merck was ranked fourth in sales among pharmaceutical companies. Merck had released the drug Vioxx‚ for treating Osteoarthritis in late 1990. Merck as a company has a reputation of being one of the most ethical and
Premium Marketing Brand Management
about the decision in terms of the CSR pyramid. Did Merck have an ethical obligation to proceed with development of the drug? Would it matter if the drug had only a small chance to cure river blindness? Does it depend on how close the company was to achieving a cure‚ or how sure they were that they could achieve it? Or does this decision become a question of philanthropy
Premium Integrity Pharmaceutical drug Onchocerciasis
research scientist working for Merck and Company‚ discovered evidence that one of the company’s drugs might kill the parasite that causes river blindness. He then decided to request permission to research this new finding. The mangers for the company noticed that it would take enormous amount of funding and time to develop this new vaccine. This new product could be really hard to market and who was going to actually buy it; it could also damaged the market share that Merck currently had by selling
Premium Medicine Science Physician
2011). In 1978‚ Merck‚ while testing invermectin (a parasite killing drug for animals)‚ found that invermectin killed a parasite similar to the one that caused river blindness. The problem for Merck was that river blindness generally only affects people in very poor areas and there was very little chance to recoup their financial investment by selling the drug. The ethical dilemma represented by this situation is focused on what course of action Merck should take. Does Merck invest precious resources
Premium Ethics Decision making Onchocerciasis
teenagers‚ police‚ parents‚ experts‚ young people‚ and other public express their opinions about how to tackle this severe problem. Some of them claim that laws and restrictions should be reinforced as they are the most effective way‚ while others argue that more resources should be committed into education. Undoubtedly‚ we should try any possible method that might help reduce the death and injuries of young drivers. But after all‚ laws and restrictions are the most fundamental solution. The characteristics
Premium Driver's license Driving Driver's education
Introduction and Situational Analysis Merck and River Blindness ethical dilemma is whether to pursue research that may or may affect the profits‚ or to choose a safer choice and go for profit rather than researching the drug. The outcome from researching the drug could possibly lead to healing the deadly and dangerous disease known as River Blindness. This drug is known to kill the parasite that has caused the disease. The problem with this situation was that the consumers of the drug could not pay
Premium Pharmacology Medicine Ethics
strategy to win the bid‚ first thing that the company need to consider is whether to bid or not to bid. To make a decision to bid or not‚ the company need to consider their human resources‚ time and cost. The company cannot make decision only on the probability of winning the bid‚ but also they need to consider the possibility that they can accomplish the project successfully following the agreement. In this competitive bidding process‚ number of companies are selected by the client to bid for the proposed
Premium Management Economics Marketing
Merck: Business Analysis Merck is a flourishing research-driven pharmaceutical company‚ which discovers‚ develops‚ manufacturers‚ and promotes an extensive variety of human and animal health products. Although Merck is one of the biggest pharmaceutical companies of the world‚ they still come across problems today while striving to sustain a lead against its competition. Merck has achieved success with its lengthy history of breakthrough drugs and the development of three significant pharmaceutical
Premium Human resource management Pharmaceutical industry Human resources
Case Study: Merck Acquisition of Medco Professor Daniel Weiss FI561 January 23‚ 2011 Case Study: Merck Acquisition of Medco Abstract The purpose of this case study is to determine whether it would be beneficial to merge Merck Corporation with Medco Containment Services Incorporated. The merger and acquisition between the world’s largest drug manufacturer and the largest prescription benefits management company (PBM) and marketer of mail order medicines in the United States would result
Premium Mergers and acquisitions Due diligence